Versantis raises CHF16m in Series B financing
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 983 entries already.
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Danish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (1.76bn) to acquire Alder BioPharmaceuticals Inc.
Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
French biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
Antibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
Glucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.